2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
GlobalData on MSN5d
FDA approves BridgeBio’s Attruby for ATTR-CM treatmentThe US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
3don MSNOpinion
See the new treatment that will break a Pfizer monopoly on a drug for heart disease.
TipRanks on MSN8d
BridgeBio announces FDA approved Attruby for ATTR-CM patientsPharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback